Celator Pharma Cash Flow - Annual (NASDAQ:CPXX)

Add to My Stocks
$30.24 $0 (0%) CPXX stock closing price Jul 14, 2016 (Closing)

The Celator Pharma cash flow statement is one of the three reports that the company generates every quarter. Financials statements like the Celator Pharma income statement and Celator Pharma balance sheet show that the company has profits and debt, while the cash flow statement provides details of cash flow movments. Celator Pharma saw a cash impact of $2.07M from the issuance of CPXX shares. The cash flow statement helps in the Celator Pharma stock analysis by providing more information for evaluating changes in assets, liabilities and equities. Celator Pharma has a negative cash and cash equivalents change of $-9.16M.

View details of Celator Pharma cash flows for latest & last 10 financial years
show more
Fiscal year is Jan - Dec20152014201320122011
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow-----
Net Increase (Decrease) in Assets Liabilities1.39M--0.02M1.24M-1.63M
Cash From (used in) Discontinued Operations-----
Other Adjustments Net2.23M1.68M8.21M4.27M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.05M-0.06M-0.04M--0.09M
Acquisition Disposition of Subsidiaires-----
Increase (Decrease) in Investments-----
Other Cash Inflow (Outflow) from Investment Activities-----
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares2.07M14.92M32.52M6.76M5M
Issuance (Repayment) of Debt Securities4.57M9.82M-3M5.42M2.52M
Increase (Decrease) in Bank & Other Borrowings-----
Payment of Dividends & Other Cash Distributions-----
Other Cash from (used by) Financing Activities-0.23M-1.43M-3.07M-0.83M-0.01M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.03M-0.01M---
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year32.41M23.58M9.64M3.22M10.39M
Cash & Equivalents at Year End23.25M32.41M23.58M9.64M3.22M
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Akorn financial analysis

Celator Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Celator Pharma stock price history.
The statement of cash flows can be categorized into three main sections:

  • Celator Pharma had a Net Change in Cash and Cash Equivalents of $-9.16M for the latest year 2015. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Celator Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Celator Pharma lost $-15.49M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash from investing stood at a negative value of $-0.05M for CPXX stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Celator Pharma earned $6.41M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Annual Cash Flow Statements For Celator Pharmaceuticals Inc Peers

Akorn cash flow, Ambit Biosciences cash flow, CTI BioPharma cash flow, Relypsa cash flow